Existing backer Bayer will invest $35m through a private placement alongside an initial public offering in which the gene editing company is initially looking to raise $90m.

Novartis has co-led a $17m series A round for Inflazome, which is working on treatments for a range of chronic inflammatory diseases.

Aalto University spinout Canatu Oy has secured $11.3m in funding adding to a $13.5m loan provided by European Investment Bank earlier this summer.

Alkemics, a smart data platform that helps manufacturers manage product details, has added $22.5m to its coffers following a series B round backed by SEB.

Email contact management tool Evercontact will also be the first startup to join the insurance group's AXA Factory accelerator.

Vivasure Medical has closed an $18.3m series C round co-led by Evonik Venture Capital and will use the cash to commercialise its blood vessel closure device.

Oxford University's commercialisation arm has appointed Matt Perkins as its new chief executive, replacing Tom Hockaday who stepped down earlier this year.